Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;105(9):659-665.
doi: 10.1002/cyto.a.24886. Epub 2024 Aug 6.

OMIP-105: A 30-color full-spectrum flow cytometry panel to characterize the immune cell landscape in spleen and tumor within a syngeneic MC-38 murine colon carcinoma model

Gabriel DeNiro  1 , Kathryn Que  1 , Trevor Fujimoto  1 , Soo Min Koo  1 , Bridget Schneider  1 , Anandaroop Mukhopadhyay  1 , Jeong Kim  1 , Anandi Sawant  1 , Tuan Andrew Nguyen  1
Affiliations
Free article

OMIP-105: A 30-color full-spectrum flow cytometry panel to characterize the immune cell landscape in spleen and tumor within a syngeneic MC-38 murine colon carcinoma model

Gabriel DeNiro et al. Cytometry A. 2024 Sep.
Free article

Abstract

This panel was designed to characterize the immune cell landscape in the mouse tumor microenvironment as well as mouse lymphoid tissues (e.g., spleen). As an example, using the MC-38 mouse syngeneic tumor model, we demonstrated that we could measure the frequency and characterize the functional status of CD4 T cells, CD8 T cells, regulatory T cells, NK cells, B cells, macrophages, granulocytes, monocytes, and dendritic cells. This panel is especially useful for understanding the immune landscape in "cold" preclinical tumor models with very low immune cell infiltration and for investigating how therapeutic treatments may modulate the immune landscape.

Keywords: flow cytometry; high dimensional; immunophenotyping; immunotherapy; mouse; spectral; syngeneic; tumor.

PubMed Disclaimer

References

REFERENCES

    1. Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651–668.
    1. Das S, Johnson DB. Immune‐related adverse events and anti‐tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):306.
    1. Zhou B, Gao Y, Zhang P, Chu Q. Acquired resistance to immune checkpoint blockades: the underlying mechanisms and potential strategies. Front Immunol. 2021;12:693609.
    1. Varayathu H, Sarathy V, Thomas BE, Mufti SS, Naik R. Combination strategies to augment immune check point inhibitors efficacy ‐ implications for translational research. Front Oncol. 2021;11:559161.
    1. Nemoto S, Mailloux AW, Kroeger J, Mulé JJ. OMIP‐031: immunologic checkpoint expression on murine effector and memory T‐cell subsets. Cytometry A. 2016;89(5):427–429.

LinkOut - more resources